Ignite Creation Date:
2024-05-06 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 12:43 PM
Study NCT ID:
NCT03481257
Status:
COMPLETED
Last Update Posted:
2018-03-29
First Post:
2018-03-21
Brief Title:
Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
Comparison of Shear Stress-induced Thrombotic and Thrombolytic Effect d Thrombolytic Effect Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel in Patients With Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A total of 50 participants diagnosed with ACS group A ticagrelor 180mgd n25 group B clopidogrel 75mg rivaroxaban 5mg d n25 were consecutively enrolled and treated with study drugs on top of aspirin 100mgd for 1 month VerifyNow and Global thrombosis test were performed at day 2 and 1 month after administration of study drugs The investigators compared aspirin reaction unit ARU and P2Y12 reaction unit PRU occlusion time OT which reflects shear stress-induced thrombotic activity and lysis time LT which showed endogenous lytic activity between the two strategies at both time points
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None